Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab.

Blas, Leandro; Shiota, Masaki; Tsukahara, Shigehiro; Nagakawa, Shohei; Matsumoto, Takashi; Eto, Masatoshi

Blas, Leandro; Shiota, Masaki; Tsukahara, Shigehiro; Nagakawa, Shohei; Matsumoto, Takashi; Eto, Masatoshi.

Afiliação

Blas L; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: shiota.masaki.101@m.kyushu-u.ac.jp.
Tsukahara S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nagakawa S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Matsumoto T; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Clin Genitourin Cancer ; 22(1): e122-e127.e1, 2024 02.

Article em En | MEDLINE | ID: mdl-37813699

Assuntos

Anilidas; Carcinoma de Células Renais; Neoplasias Renais; Piridinas; Humanos; Nivolumabe; Ipilimumab; Carcinoma de Células Renais/secundário; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Neoplasias Renais/patologia

Palavras-chave

Adverse Event Reporting System; Food and Drug Administration; Kidney neoplasm

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Carcinoma de Células Renais / Neoplasias Renais / Anilidas Limite: Humans Idioma: En Revista: Clin Genitourin Cancer Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google